A retrospective analysis of the safety profile of intravenous immunoglobulin in 1176 patients receiving home infusion therapy

TY - JOUR

T1 - A retrospective analysis of the safety profile of intravenous immunoglobulin in 1176 patients receiving home infusion therapy

AU - Souayah, Nizar

AU - Pahwa, Ankit

AU - Burawski, Lauren

AU - Opila, Tamara

AU - Sander, Howard W.

N1 - Publisher Copyright: © 2017 Wolters Kluwer Health, Inc.

PY - 2018

Y1 - 2018

N2 - Objectives: This analysis assessed the safety of intravenous immunoglobulin (IVIg) in the treatment of patients with neuroimmunological and immunological disorders in a home-based setting. Methods: Adverse reactions (ARs) were assessed in a retrospective review of 1176 patients receiving 28,677 home-based IVIg infusions between 1996 and 2013. Results: Of 1176 patients, 648 (55.1%) experienced IVIgrelated ARs; 536 (45.6%) were mild, 78 (6.6%) moderate, and 34 (2.9%) severe. Thirty-seven (3.1%) patients were hospitalized because of ARs; of these, headache was most common (51.4%). Mean number of ARs per patient increased from 1.4 (low dose) to 3.6 (high dose). Incidence of ARs increased from 41% in the first 5-year moving average in 2003 to 65% in 2008. The number of ARs correlated with the number of infusions (r =0.24; P < 0.001) and the average IVIg dose (r =0.10; P < 0.001). Conclusions: Low- and high-dose IVIg were safe and well tolerated with a few serious ARs in patients with neuroimmunological and immunological disorders.

AB - Objectives: This analysis assessed the safety of intravenous immunoglobulin (IVIg) in the treatment of patients with neuroimmunological and immunological disorders in a home-based setting. Methods: Adverse reactions (ARs) were assessed in a retrospective review of 1176 patients receiving 28,677 home-based IVIg infusions between 1996 and 2013. Results: Of 1176 patients, 648 (55.1%) experienced IVIgrelated ARs; 536 (45.6%) were mild, 78 (6.6%) moderate, and 34 (2.9%) severe. Thirty-seven (3.1%) patients were hospitalized because of ARs; of these, headache was most common (51.4%). Mean number of ARs per patient increased from 1.4 (low dose) to 3.6 (high dose). Incidence of ARs increased from 41% in the first 5-year moving average in 2003 to 65% in 2008. The number of ARs correlated with the number of infusions (r =0.24; P < 0.001) and the average IVIg dose (r =0.10; P < 0.001). Conclusions: Low- and high-dose IVIg were safe and well tolerated with a few serious ARs in patients with neuroimmunological and immunological disorders.

KW - Home infusion

KW - IVIg

KW - Immunological

KW - Neuroimmunological

KW - Neuromuscular

UR - http://www.scopus.com/inward/record.url?scp=85051870567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051870567&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/CND.0000000000000201

DO - https://doi.org/10.1097/CND.0000000000000201

M3 - Article

C2 - 29794573

VL - 19

SP - 181

EP - 195

JO - Journal of clinical neuromuscular disease

JF - Journal of clinical neuromuscular disease

SN - 1522-0443

IS - 4

ER -